Interview: Prof. Dr. Murat Özgören – Vice-Rector, Dokuz Eylül…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Dokuz Eylül Health Technopark DEPARK
The first thematic health technopark in Turkey that is fully integrated with hospital, research centers and medical schools. It is an ideal location for biotech and medical device companies inb Turkey for R&D, product development and soft-landing. DEPARK has started medical technopark services at its mother building ZEYTIN. The name zeytin refers to olives and it stands for 3500 years lifespan of olive trees while still producing olives. It also refers to natural health remedies that are attached to the olive (e.g. as in the movie Lorenzo’s Oil). There is a specifically medicine oriented technology transfer office called DETTO (Dokuz Eylül Technology Transfer Office). It has a wide variety of services from international soft landing, tax and law support, IP rights management, incubation, technical consultancy, funding, clinical trials, pre-clinical consultation to marketing and guidance for international partnering. The hosting university, Dokuz Eylül University, has 14 faculties (app 67,000 students) to support the larger ecosystem for a wide range of activities and research. The ecosystem includes a university hospital over 1,100 beds, medical school, medical graduate study programs, medical research institutes (ie oncology, genome etc), nearly 1,000 academics, health technologies accelerator, associate service study programs like nursing, health technicians, sports technologies, physiotherapy center, medical devices calibration center and home-care research center.
BioIzmir
BioIzmir is an international gateway project for creating a one-stop-shop ecosystem for biotech and medical devices. It is located within a health technopark (DEPARK) embedded into a hospital complex.
From design to manufacturing, process to IPR rights this will be a critical partner for companies and development/tech transfer organizations. Izmir Health Technologies Development and Accelerator Center will serve as a hub of the essential elements known in medical circle as “from the laboratory bench to the patient’s bedside”. The structure of the Center will provide “one-stop-shop” aimed to establish Izmir as the intersection of health enterprise and innovation in regional, national and international contexts. The activities within the scope of the project will create an eco system in which integration occurs between the industry and the dynamics of R&D and innovation.
iBG-izmir
Dokuz Eylul University Izmir Biomedicine and Genome Center (iBG-izmir) is developed within “Bioİzmir” Science and Technology Park, which is the result of the innovative partnership of DEU Health Campus, the Faculty of Medicine & University Hospital and the Health Themed Technopark (DEPARK). iBG is the first such regional hub, with headquarters in Izmir, Turkey’s third largest city and a critical locomotive for growing Turkish economy, particularly within the health sector. iBG’s vision is to establish a most prominent center for health and life sicences in South-West Europe and MENA countries in a 10 years period. This comprehensive regional hub will be multidisciplinary in approach and shall bring molecular biology, genetics, medicine, pharmaceutical sciences, bioengineering, computer engineering and many other fields together. iBG-izmir will open its doors in 09-10 Sep 2015 with including Nobel session and reception.
Contact
Dokuz Eylül Üniversitesi İnciraltı Yerleşkesi Balçova
35340 İzmir Türkiye
Tel: +90 (232) 412 80 00
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Turkey’s former minister of health explains how he is working to pass on his experience and knowledge to the next generation of health policy makers around the world, and discusses the…
The president of Turkey’s social security institution, the SGK, discusses the evolution of healthcare spending over the past three years, and the underpinning principles guiding their drug reimbursement policy decisions.…
In the global theater of business and politics, Turkey increasingly leverages its location as an ideal vantage point where actors can seamlessly move between all things West and East. An…
Within the Ministry’s wide scope of activities aimed at promoting Turkish various industries and trade, what special role does the pharmaceutical sector play within these aspirations? The world we live…
Focus Reports has been here a bit more than three months, and heard different opinions. Some said highlighted Turkey’s strategic advantages – population, age distribution, geography, political and economic stability…
Would you like to provide our international readers with a brief introduction into Novo Nordisk’s Turkish affiliate? As you may know, Novo Nordisk has a rich history of over 85…
You are managing partner of Egon Zehnder Turkey since 2007. Could you start by introducing the company to our readers and its scope of activities in Turkey? Egon Zehnder International…
Omega CRO was the first clinical trial company in Turkey. A few years later, in 2002, we saw a sharp increase of similar businesses, including Quintiles. What spurred the establishment…
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
Cegedim has become a very strong partner for pharmaceutical companies worldwide, including Turkey. Nevertheless, with respect to healthcare, there are probably as many systems as countries. How does Cegedim adapt…
Pharmaceutical Executive and Focus Reports are of course about the industry but also about the people making it happen. So before anything would you like to introduce yourself to our…
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
See our Cookie Privacy Policy Here